Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anniek K. D. Visser is active.

Publication


Featured researches published by Anniek K. D. Visser.


Neurobiology of Learning and Memory | 2008

Transgenic inhibition of neuronal calcineurin activity in the forebrain facilitates fear conditioning, but inhibits the extinction of contextual fear memories

Robbert Havekes; Ingrid M. Nijholt; Anniek K. D. Visser; Ulrich Eisel; Eddy A. Van der Zee

It is unclear whether protein phosphatases, which counteract the actions of protein kinases, play a beneficial role in the formation and extinction of previously acquired fear memories. In this study, we investigated the role of the calcium/calmodulin dependent phosphatase 2B, also known as calcineurin (CaN) in the formation of contextual fear memory and extinction of previously acquired contextual fear. We used a temporally regulated transgenic approach, that allowed us to selectively inhibit neuronal CaN activity in the forebrain either during conditioning or only during extinction training leaving the conditioning undisturbed. Reducing CaN activity through the expression of a CaN inhibitor facilitated contextual fear conditioning, while it impaired the extinction of previously formed contextual fear memory. These findings give the first genetic evidence that neuronal CaN plays an opposite role in the formation of contextual fear memories and the extinction of previously formed contextual fear memories.


European Journal of Nuclear Medicine and Molecular Imaging | 2011

Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications

Anniek K. D. Visser; Aren van Waarde; Antoon T. M. Willemsen; Fokko J. Bosker; Paul G.M. Luiten; Johan A. den Boer; Ido P. Kema; Rudi Dierckx

The serotonergic system of the brain is complex, with an extensive innervation pattern covering all brain regions and endowed with at least 15 different receptors (each with their particular distribution patterns), specific reuptake mechanisms and synthetic processes. Many aspects of the functioning of the serotonergic system are still unclear, partially because of the difficulty of measuring physiological processes in the living brain. In this review we give an overview of the conventional methods of measuring serotonin synthesis and methods using positron emission tomography (PET) tracers, more specifically with respect to serotonergic function in affective disorders. Conventional methods are invasive and do not directly measure synthesis rates. Although they may give insight into turnover rates, a more direct measurement may be preferred. PET is a noninvasive technique which can trace metabolic processes, like serotonin synthesis. Tracers developed for this purpose are α-[11C]methyltryptophan ([11C]AMT) and 5-hydroxy-L-[β-11C]tryptophan ([11C]5-HTP). Both tracers have advantages and disadvantages. [11C]AMT can enter the kynurenine pathway under inflammatory conditions (and thus provide a false signal), but this tracer has been used in many studies leading to novel insights regarding antidepressant action. [11C]5-HTP is difficult to produce, but trapping of this compound may better represent serotonin synthesis. AMT and 5-HTP kinetics are differently affected by tryptophan depletion and changes of mood. This may indicate that both tracers are associated with different enzymatic processes. In conclusion, PET with radiolabelled substrates for the serotonergic pathway is the only direct way to detect changes of serotonin synthesis in the living brain.


Journal of Psychopharmacology | 2010

Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood–brain barrier: an experimental PET study in rats

Onno L. de Klerk; Fokko J. Bosker; Antoon T. M. Willemsen; Aren van Waarde; Anniek K. D. Visser; Tim de Jager; Girstaute Dagyte; Johan A. den Boer; Rudi Dierckx; Peter Meerlo

The multi-drug efflux transporter P-glycoprotein is expressed in high concentrations at the blood—brain barrier and has a major function in the transport of drugs. In a recent PET-study evidence was found for an increased function of P-glycoprotein at the blood—brain barrier in medicated patients suffering from major depressive disorder. We used small-animal PET and [11C]-verapamil to study P-glycoprotein function at the blood—brain barrier of rats, either being administered as venlafaxine, an antidepressant, or subjected to chronic stress, a factor contributing to the development of depression. In a first experiment, male Wistar rats underwent a three-week foot shock procedure as a model of human depression. In a second experiment, rats were chronically treated with the antidepressant venlafaxine (25 mg/kg/d via an implanted osmotic minipump). In both experiments, a [11C]-verapamil PET scan was performed. In the chronically stressed rats, the distribution volume (VT) of [11C]-verapamil was significantly increased, whereas treatment with venlafaxine had the opposite effect and caused a significant reduction in VT. The changes in VT could not be attributed to the influx rate constant (K1). Our data suggest that P-glycoprotein function at the blood—brain barrier is inhibited by chronic stress and increased by chronic administration of venlafaxine.


The Journal of Nuclear Medicine | 2012

11C-Hydroxytryptophan Uptake and Metabolism in Endocrine and Exocrine Pancreas

Valentina Di Gialleonardo; Alberto Signore; Ena A. Scheerstra; Anniek K. D. Visser; Aren van Waarde; Rudi Dierckx; Erik F. J. de Vries

Determination of the residual β-cell mass using noninvasive tools might help to follow up the efficacy of new treatments in both type 1 (insulin-dependent) and type 2 (non–insulin-dependent) diabetes mellitus, including islet transplantation. β-cells are neuroendocrine cells that can take up and metabolize the serotonin precursor 5-hydroxytryptophan. The serotonin pathway may therefore be an attractive target for the development of an imaging tracer for residual β-cell mass. The aim of this study was to evaluate the uptake mechanism and the retention of the PET tracer 11C-hydroxytryptophan in endocrine and exocrine pancreas in vitro and in vivo. Methods: The exocrine human pancreas carcinoma cell line (PANC-1) and the endocrine human insulinoma cell line (CM) were applied for in vitro 11C-hydroxytryptophan accumulation/efflux experiments and blocking studies using inhibitors of key enzymes and transporters involved in the serotonin pathway. Animal experiments were performed on normal Wistar rats and on rats pretreated with the monoamine oxidase (MAO) inhibitor clorgyline. After intravenous injection of 11C-hydroxytryptophan, a 60-min dynamic PET scan was acquired followed by an ex vivo biodistribution study. Autoradiography and hematoxylin–eosin staining were performed on the dissected pancreas to localize the radioactivity within the pancreatic tissue. Results: 11C-hydroxytryptophan accumulated rapidly in both endocrine CM cells and exocrine PANC-1 cells. In the exocrine cells, a rapid efflux of radioactivity was observed, whereas most radioactivity remained trapped in the endocrine cells. PET images showed clear accumulation of 11C-hydroxytryptophan in the pancreas in both animal groups, but with a significant 3-fold higher retention of the radiopharmaceutical in clorgyline-treated animals. Ex vivo biodistribution studies confirmed the results obtained by PET. Autoradiographs did not discriminate between the exocrine and endocrine pancreas in control animals, whereas autoradiographs showed intense radioactive spots colocalized with the islets of Langerhans in clorgyline-treated animals. Conclusion: 11C-hydroxytryptophan is trapped in β-cells but not in exocrine pancreatic cells. β-cell selectivity can be strongly enhanced by inhibition of MAO-A. This observation offers perspectives for the development of a more selective PET tracer for β-cell mass, based on an 11C-hydroxytryptophan derivative with increased resistance toward degradation by MAO-A.


The Journal of Nuclear Medicine | 2013

Small-Animal PET with a σ-Ligand, 11C-SA4503, Detects Spontaneous Pituitary Tumors in Aged Rats

Nisha Kuzhuppilly Ramakrishnan; Anna A. Rybczynska; Anniek K. D. Visser; Krisztina Marosi; Csaba Nyakas; Chantal Kwizera; Jurgen W. A. Sijbesma; Philip H. Elsinga; Kiichi Ishiwata; Jan Pruim; Rudi Dierckx; Aren van Waarde

Pituitary tumors are often detected only after death or at late stages of the disease when they are macroadenomas with a low surgical cure rate. Spontaneous pituitary tumors occur in rats over 1 y of age. In an ongoing study of changes in σ-1 agonist binding related to aging, several of our rats developed such tumors. The aim of the current study was to assess the kinetics of 11C-SA4503 (11C-labeled 1-[2-(3,4-dimethoxyphenthyl)]-4-(3-phenylpropyl)-piperazine dihydrochloride) in tumor and brain and to evaluate the utility of this tracer in the detection of pituitary tumors. Methods: Small-animal PET scans of the brain region of male Wistar Hannover rats (age, 18–32 mo) were acquired using the σ-1 agonist tracer 11C-SA4503. The time-dependent uptake of 11C in the entire brain, tumor or normal pituitary, and thyroid was measured. A 2-tissue-compartment model was fitted to the PET data, using metabolite-corrected plasma radioactivity as the input function. Results: Pituitary tumors showed up as bright hot spots in the scans. The total distribution volume (VT) of the tracer was significantly higher in the tumor than in the normal pituitary. Surprisingly, a higher VT was also seen in the brain and thyroid tissue of animals with pituitary tumors than in healthy rats. The increase in VT in the brain and thyroid was not related to a change in nondisplaceable binding potential (BPND) but rather to an increase in the partition coefficient (K1/k2) of 11C-SA4503. The increase in VT in the tumor on the other hand was accompanied by a significant increase in BPND. Western blotting analysis indicated that pituitary tumors overexpressed σ-1 receptors. Conclusion: The overexpression of σ-1 receptors in spontaneous pituitary tumors is detected as an increase in uptake and BPND of 11C-SA4503. Therefore, this tracer may have promise for the detection of pituitary adenomas, using PET.


Neurochemistry International | 2015

Serotonin-2C antagonism augments the effect of citalopram on serotonin and dopamine levels in the ventral tegmental area and nucleus accumbens.

Anniek K. D. Visser; Jelle Kleijn; Martijn van Faassen; Eliyahu Dremencov; Gunnar Flik; Ido P. Kema; Johan A. den Boer; Aren van Waarde; Rudi A. J. O. Dierckx; Fokko J. Bosker

Many patients with major depression do not respond to selective serotonin reuptake inhibitors (SSRIs). Lack of response could be due to inhibition of dopamine (DA) release by serotonin (5-HT) through 5-HT2C receptors. Combining an SSRI with a 5-HT2C antagonist may result in improved efficacy by causing simultaneous increases of 5-HT and DA. In order to test this augmentation strategy, male Wistar rats were treated (s.c.) with an acute dose of the SSRI citalopram (Cit, 5 mg/kg), the 5-HT2C antagonist SB 242084 (SB, 2 mg/kg), or Cit + SB, and the effect on 5-HT and DA release in the nucleus accumbens (NAcc) was assessed by microdialysis. In a separate experiment, animals were treated with vehicle, Cit (20 mg/kg/d), SB (2 mg/kg/d) or Cit + SB for a period of 2 days (s.c.), and the impact on the release of 5-HT and DA in the ventral tegmental area (VTA) and NAcc was studied. On the day of microdialysis, 5-HT2C receptor sensitivity was assessed with an SB challenge. Acutely administered Cit + SB increased 5-HT release in the NAcc more than Cit alone. SB alone increased DA release in the NAcc (not in the VTA), but when administered together with Cit, this effect was abolished. A 2-day treatment with Cit or Cit + SB increased 5-HT release in both VTA and NAcc. Combining Cit with SB augmented the effect of Cit in the VTA. DA release in VTA and NAcc was only significantly increased after 2-days of treatment with Cit + SB. In conclusion, Cit + SB had synergistic effects on 5-HT and DA release after 2-days of treatment, probably related to a decreased tonic inhibition of DA release via 5-HT2C receptors. Regional differences occur and future studies should elucidate if this augmentation strategy is beneficial at the behavioral level.


Synapse | 2014

Acute social defeat does not alter cerebral 5-HT2A receptor binding in male Wistar rats.

Anniek K. D. Visser; Peter Meerlo; Anders Ettrup; Gitte M. Knudsen; Fokko J. Bosker; Johan A. den Boer; Rudi A. J. O. Dierckx; Aren van Waarde

It has been hypothesized that effects of uncontrollable stress on serotonin receptor expression contribute to the etiology of stress‐related disorders like depression. While the serotonin‐2A receptors (5‐HT2AR) are thought to be important in this context, only few studies examined effects of stress on this receptor subtype. In this study, we therefore assessed acute and long‐term changes in 5HT2AR binding after social defeat stress in rats. Male Wistar rats were subjected to social defeat by placing them in the home cage of an aggressive, dominant Long Evans rat. Acute social defeat suppressed growth, but did not affect anxiety‐like behavior in an open field test. A positron emission tomography scan with the 5‐HT2AR tracer [11C]MDL 100907 1 day and 3 weeks after defeat did not show significant changes in receptor binding. To verify these results, [3H]MDL 100907 binding assays were performed in homogenates of prefrontal cortex and hippocampus, which also did not indicate any changes in Bmax or Kd. These findings do not support the hypothesis that changes in 5‐HT2AR function are a vital mechanism through which uncontrollable stress contributes to stress‐related pathologies such as depression. It remains to be determined whether effects of stress on 5HT2AR binding depend on the nature of the stressor or on the characteristics of the rat strain. Synapse, 2014.


PET and SPECT in psychiatry | 2014

Molecular Imaging of Depressive Disorders

Henricus G. Ruhé; Anniek K. D. Visser; Vibe G. Frokjaer; Bartholomeus C.M. (‘Benno’) Haarman; Hans C. Klein; Jan Booij

This chapter summarizes findings of a large number of molecular imaging studies in the field of unipolar and bipolar depression (BD).


Journal of Cerebral Blood Flow and Metabolism | 2014

[(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.

Anniek K. D. Visser; Nisha Kuzhuppilly Ramakrishnan; Antoon T. M. Willemsen; Valentina Di Gialleonardo; Erik F. J. de Vries; Ido P. Kema; Rudi A. J. O. Dierckx; Aren van Waarde

The PET tracer [11C]5-hydroxytryptophan ([11C]5-HTP), which is converted to [11C]5-hydroxytryptamine ([11C]5-HT) by aromatic amino acid decarboxylase (AADC), is thought to measure 5-HT synthesis rates. But can we measure these synthesis rates by kinetic modeling of [11C]5-HTP in rat? Male rats were scanned with [11C]5-HTP (60 minutes) after different treatments. Scans included arterial blood sampling and metabolite analysis. 5-HT synthesis rates were calculated by a two-tissue compartment model (2TCM) with irreversible tracer trapping or Patlak analysis. Carbidopa (inhibitor peripheral AADC) dose-dependently increased [11C]5-HTP brain uptake, but did not influence 2TCM parameters. Therefore, 10 mg/kg carbidopa was applied in all subsequent study groups. These groups included treatment with NSD 1015 (general AADC inhibitor) or p-chlorophenylalanine (PCPA, inhibitor of tryptophan hydroxylase, TPH). In addition, the effect of a low-tryptophan (Trp) diet was investigated. NSD 1015 or Trp depletion did not affect any model parameters, but PCPA reduced [11C]5-HTP uptake, and the k3. This was unexpected as NSD 1015 directly inhibits the enzyme converting [11C]5-HTP to [11C]5-HT, suggesting that trapping of radioactivity does not distinguish between parent tracer and its metabolites. As different results have been acquired in monkeys and humans, [11C]5-HTP-PET may be suitable for measuring 5-HT synthesis in primates, but not in rodents.


Synapse | 2015

Similar serotonin-2A receptor binding in rats with different coping styles or levels of aggression

Anniek K. D. Visser; Anders Ettrup; Anders Bue Klein; Aren van Waarde; Fokko J. Bosker; Peter Meerlo; Gitte M. Knudsen; Sietse F. de Boer

Individual differences in coping style emerge as a function of underlying variability in the activation of a mesocorticolimbic brain circuitry. Particularly serotonin seems to play an important role. For this reason, we assessed serotonin‐2A receptor (5‐HT2AR) binding in the brain of rats with different coping styles. We compared proactive and reactive males of two rat strains, Wild‐type Groningen (WTG) and Roman high‐ and low avoidance (RHA, RLA). 5‐HT2AR binding in (pre)frontal cortex (FC) and hippocampus was investigated using a radiolabeled antagonist ([3H]MDL‐100907) and agonist ([3H]Cimbi‐36) in binding assays. No differences in 5‐HT2AR binding were observed in male animals with different coping styles. [3H]MDL‐100907 displayed a higher specific‐to‐nonspecific binding ratio than [3H]Cimbi‐36. Our findings suggest that in these particular rat strains, 5‐HT2AR binding is not an important molecular marker for coping style. Because neither an antagonist nor an agonist tracer showed any binding differences, it is unlikely that the affinity state of the 5‐HT2AR is co‐varying with levels of aggression or active avoidance in WTG, RHA and RLA. Synapse, 69:226–232, 2015.

Collaboration


Dive into the Anniek K. D. Visser's collaboration.

Top Co-Authors

Avatar

Aren van Waarde

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Rudi Dierckx

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Nisha Kuzhuppilly Ramakrishnan

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Rudi A. J. O. Dierckx

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Fokko J. Bosker

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Johan A. den Boer

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna A. Rybczynska

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Chantal Kwizera

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Ido P. Kema

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge